SCHEMBL22845373

SCHEMBL22845373

CNC(=O)c1ccc(-n2c(=O)c3c(n4ncc(NCc5ccccc5F)c24)CN(C(=O)c2ccc(Br)c(Cl)c2)CC3)cc1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 3/20 0.35
PTK2 Q05397 2/20 0.33
LMNA P02545 2/20 0.33
ALDH1A1 P00352 2/20 0.33
MAPT P10636 1/20 0.33
KDM4E B2RXH2 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
HDAC8 Q9BY41 1/20 0.32
THRB P10828 1/20 0.32
MAPK14 Q16539 2/20 0.32
POLB P06746 1/20 0.32
JAK2 O60674 1/20 0.31
NTRK1 P04629 1/20 0.31
TYK2 P29597 1/20 0.31
KDR P35968 1/20 0.31
JAK3 P52333 1/20 0.31
PTK2B Q14289 1/20 0.31
NTRK3 Q16288 1/20 0.31
NTRK2 Q16620 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22845278 0.92 GRM5 (0.32) PTK2LMNAMAPK14HPGD
SCHEMBL22845388 0.91 PREP (0.35) HDAC8MAPK14MTHFD2
SCHEMBL22845527 0.90 PREP (0.37) LMNAMAPTMAPK14MAPK8MAPK10
SCHEMBL22845323 0.86 MTHFD2 (0.34) PTK2ALDH1A1KDM4EHDAC8MAPK14
SCHEMBL24483838 0.86 HDAC1 (0.35) TP53LMNAALDH1A1MAPTHDAC8
SCHEMBL22845318 0.86 PRLHR (0.33)
SCHEMBL22845234 0.85 PRLHR (0.34) TP53LMNAALDH1A1MAPTMEN1
SCHEMBL24173968 0.85 PRLHR (0.36) MAPTPOLBKDRMAPK8MAPK10
SCHEMBL22845506 0.85 S1PR2 (0.34) PTK2ALDH1A1MAPTMEN1KMT2A
SCHEMBL22845379 0.85 PREP (0.36) LMNAALDH1A1MAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220000874-A1 TRICYCLIC COMPOUNDS ALIGOS THERAPEUTICS, INC. 2022-01-06 US disclosed
US-11136321-B2 Tricyclic compounds ALIGOS THERAPEUTICS, INC. (US) 2021-10-05 US disclosed
US-20200407361-A1 TRICYCLIC COMPOUNDS ALIGOS THERAPEUTICS, INC. 2020-12-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220000874-A1 TRICYCLIC COMPOUNDS SLC10A1, PKD1, CEL TP53 1710/4885PTK2 4823/4885LMNA 1680/4885
US-11136321-B2 Tricyclic compounds SLC10A1, PKD1, CEL TP53 1710/4885PTK2 4823/4885LMNA 1680/4885
US-20200407361-A1 TRICYCLIC COMPOUNDS SLC10A1, PKD1, CEL TP53 1710/4885PTK2 4823/4885LMNA 1680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.